Inventor · disambiguated record
Nava Zisapel
Also filed as: ZISAPEL NAVA
27 granted patents·9 pending applications·235 citations·filing 1987–2024
96Inventor score
Files withNEURIM PHARMA 199116NEURIM PHARMACEUTICALS 1991 LTD7ZISAPEL NAVA7PINNER ELHANAN2NEURIM PHARAMACEUTICALS 1991 L1
Top patents by PatentIndex Score
36 records- 0192US4880826AMelatonin antagonistZISAPEL NAVA·Filed 1987·Granted Nov 14, 1989·39 cites·5 claims
- 0290US9119846B2Method and composition for enhancing cognition in alzheimer's patientsNEURIM PHARMA 1991·Filed 2014·Granted Sep 1, 2015·6 cites·19 claims
- 0386US8075914B2Method and formulation for treating resistance to antihypertensives and related conditionsZISAPEL NAVA·Filed 2007·Granted Dec 13, 2011·7 cites·9 claims
- 0485US8728511B2Method of treatment comprising administering controlled release melatoninZISAPEL NAVA·Filed 2011·Granted May 20, 2014·7 cites·6 claims
- 0585US5498423AMethod for correcting plasma melatonin levels and pharmaceutical formulation comprising melatoninNEURIM PHARMA 1991·Filed 1994·Granted Mar 12, 1996·48 cites·10 claims
- 0684US6566389B1Therapeutic uses of melatoninNEURIM PHARMA 1991·Filed 2000·Granted May 20, 2003·21 cites·11 claims
- 0781US6780884B2Derivating of tryptamine and analogous compounds and pharmaceutical formulations containing themNEURIM PHARMA 1991·Filed 2001·Granted Aug 24, 2004·13 cites·10 claims
- 0880US6858642B1Indole derivativesNEURIM PHARMA 1991·Filed 2000·Granted Feb 22, 2005·11 cites·14 claims
- 0980US6833383B2Methods for treating patients suffering from drug dependencies which lead to plasma melatonin deficienciesNEURIM PHARMA 1991·Filed 2002·Granted Dec 21, 2004·10 cites·27 claims
- 1076US7332177B1Method and formulation for treating resistance to antihypertensives and related conditionsNEURIM PHARMA 1991·Filed 2000·Granted Feb 19, 2008·7 cites·8 claims
- 1169US11807907B2Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locusNEURIM PHARMACEUTICALS 1991 LTD·Filed 2022·Granted Nov 7, 2023·0 cites·18 claims
- 1269US6469044B1Method for treating patients suffering from drug dependencies which lead to plasma melationin deficienciesNEURIM PHARMA 1991·Filed 1995·Granted Oct 22, 2002·21 cites·14 claims
- 1368US11840731B2Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locusNEURIM PHARMACEUTICALS 1991 LTD·Filed 2022·Granted Dec 12, 2023·0 cites·13 claims
- 1465US2024068035A1Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locusNEURIM PHARMACEUTICALS 1991 LTD·Filed 2023·Application pending·0 cites
- 1564US10869857B2Melatonin mini-tablets and method of manufacturing the sameNEURIM PHARMA 1991·Filed 2020·Granted Dec 22, 2020·0 cites·15 claims
- 1664US8309767B22-aminobenzoyl derivativesZISAPEL NAVA·Filed 2004·Granted Nov 13, 2012·3 cites·9 claims
- 1764US2024130968A1Methods and products for treating subjects with autism spectrum disordersNEURIM PHARMACEUTICALS 1991 LTD·Filed 2023·Application pending·0 cites
- 1863US2025057848A1Gal475 compositions and methods of use thereofNEURIM PHARMACEUTICALS 1991 LTD·Filed 2024·Application pending·0 cites
- 1961US11878016B2Methods and products for treating subjects with autism spectrum disordersNEURIM PHARMACEUTICALS 1991 LTD·Filed 2022·Granted Jan 23, 2024·0 cites·28 claims
- 2061US2024238250A1Method of using piromelatine for treating parasomnias associated with loss of rem sleep atoniaNEURIM PHARMACEUTICALS 1991 LTD·Filed 2024·Application pending·0 cites
- 2158US10722494B2Melatonin mini-tablets and method of manufacturing the sameNEURIM PHARMA 1991·Filed 2018·Granted Jul 28, 2020·0 cites·7 claims
- 2255US8859593B2Composition for improving cognition and memoryZISAPEL NAVA·Filed 2004·Granted Oct 14, 2014·0 cites·10 claims
- 2354US10849856B2Melatonin mini-tablets and method of manufacturing the sameNEURIM PHARMA 1991·Filed 2020·Granted Dec 1, 2020·0 cites·17 claims
- 2454US7355054B2Indole derivativesNEURIM PHARMA 1991·Filed 2005·Granted Apr 8, 2008·0 cites·17 claims
- 2554US5500225AMethod for determination of urine components and for preventing sudden infant death syndromeNEURIM PHARMA 1991·Filed 1993·Granted Mar 19, 1996·15 cites·18 claims
- 2653US6048888AMethod and pharmaceutical formulation for treating benign prostatic hyperplasiaNEURIM PHARAMACEUTICALS 1991 L·Filed 1997·Granted Apr 11, 2000·11 cites·4 claims
- 2753US5750557AMethod and pharmaceutical formulation for treating benign prostatic hyperplasiaNEURIM PHARMACUETICALS LTD·Filed 1993·Granted May 12, 1998·16 cites·2 claims
- 2853US2005020664A1Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing themNEURIM PHARMA 1991·Filed 2004·Application pending·0 cites
- 2953US2014378512A1Composition for improving cognition and memoryNEURIM PHARMA 1991·Filed 2014·Application pending·0 cites
- 3051US9018180B2CD44 splice variants in neurodegenerative diseasesPINNER ELHANAN·Filed 2008·Granted Apr 28, 2015·0 cites·8 claims
- 3150US2002156121A1Methods for treating patients suffering from drug dependencies which leads to plasma melatonin deficienciesNEURIM PHARMACEUTICALS·Filed 2002·Application pending·0 cites
- 3248US8461297B2Cytoplasmic malate dehydrogenase (MDH1) targeted treatment for neurodegenerative diseasesZISAPEL NAVA·Filed 2008·Granted Jun 11, 2013·0 cites·2 claims
- 3343US8962024B2Method for treating primary insomniaZISAPEL NAVA·Filed 2002·Granted Feb 24, 2015·0 cites·7 claims
- 3443US2005175692A1Pharmaceutical formulation comprising melatoninNEURIM PHARMA 1991·Filed 2003·Application pending·0 cites
- 3536US9416166B2CD44 splice variants in neurodegenerative diseasesNEURIM PHARAMCEUTICALS (1991) LTD·Filed 2015·Granted Aug 16, 2016·0 cites·17 claims
- 3626US2014045764A1Neuroprotective peptidesPINNER ELHANAN·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nava Zisapel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →